GATM polymorphism associated with the risk for statin-induced myopathy not replicated in case-control analysis of 715 dyslipidemic individuals

Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin therapy. A polymorphism affecting the gene encoding glycine amidinotransferase ( GATM rs9806699 G>A) was previously associated with reduced risk for SIM. Our objective was to replicate the GATM association in a...

Full description

Saved in:
Bibliographic Details
Published in:Cell metabolism 2015-04, Vol.21 (4), p.622-627
Main Authors: Luzum, Jasmine A., Kitzmiller, Joseph P., Isackson, Paul J., Ma, Changxing, Medina, Marisa W., Dauki, Anees M., Mikulik, Eduard B., Ochs-Balcom, Heather M., Vladutiu, Georgirene D.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin therapy. A polymorphism affecting the gene encoding glycine amidinotransferase ( GATM rs9806699 G>A) was previously associated with reduced risk for SIM. Our objective was to replicate the GATM association in a large, multicenter SIM case-control study. Mild and severe SIM cases and age- and gender-matched controls were enrolled. Participants were genotyped, and associations were tested (n=715) using chi-square and logistic regression with consideration for SIM severity and exclusion of subjects with potentially confounding co-medications. The minor allele (A) frequencies of GATM rs9806699 in the controls (n=106), mild SIM (n=324), and severe SIM (n=285) cases were 0.26, 0.28, and 0.29, respectively (p=0.447). The unadjusted odds ratio for the A allele for any SIM (mild or severe) was 1.14 (0.82–1.61; p=0.437), which remained non-significant in all models. Our results do not replicate the association between GATM rs9806699 and SIM.
ISSN:1550-4131
1932-7420
DOI:10.1016/j.cmet.2015.03.003